• AdvanDx (Woburn, Massachusetts) said it received FDA clearance of the Yeast Traffic Light PNA FISH to identify Candida yeast species directly from positive blood cultures. The Yeast Traffic Light is the latest addition to AdvanDx's molecular-based PNA FISH diagnostics platform that provides identification of bloodstream pathogens. Candidemia, a bloodstream infection caused by Candida species is one of the most serious hospital acquired infections, afflicting over 24,000 patients in the U.S. every year. AdvanDx makes molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections.

• SQI Diagnostics (Toronto) reported positive results from its external validation tests conducted at the Cleveland Clinic and Mount Sinai Hospital in Toronto. The results demonstrated that SQI's automated SQiDworks platform and QuantiSpot RA microarray consumable test performed consistently at all sites, at a level that is equivalent to the performance of FDA-approved manual diagnostic devices, while offering significantly greater efficiencies in costs and labor. The SQiDworks automated platform is used to analyze multiple-biomarkers in a fully automated "load-and-go" process. The lead test for the platform is the QuantiSpot RA assay, which provides simultaneous analysis of four biomarkers commonly prescribed to aid in the diagnosis and monitoring of rheumatoid arthritis, including the anti-CCP-IgG marker that has been adopted rapidly over the last five years.

• Varian Medical Systems (Palo Alto, California) reported the introduction of the RapidArc radiotherapy technology for speedy, precise volumetric arc IMRT. The enhanced version of RapidArc enables more versatile approaches for targeting large, irregularly shaped, or awkwardly-positioned tumors. It incorporates tools for planning and delivering IMRT treatments using one or more arcs, or multiple non-coplanar arcs, which are typically used for stereotactic radiosurgery. Using several arcs also makes it possible to treat multiple tumors simultaneously.

• Verathon (Bothell, Washington) reported the introduction of GlideScope single-use video laryngoscope products for preterm and neonatal patients. Designed for small, delicate anatomy, the GlideScope video laryngoscope Cobalt 1-2 and Ranger Single Use 1-2 provide a clear, real-time view of the child's airway, enabling quick intubation. The GlideScope preterm and neonatal devices are ideal for younger patients in fast-paced intubation settings, such as the neonatal intensive care unit, operating room and emergency department. GlideScope's design consists of a slim reusable video baton which houses a high-resolution camera with an anti-fogging mechanism to resist lens contamination; a non-glare color monitor; and single-use, sterile GVL Stats in two preterm and neonatal sizes that offer blade angulation. Providers can choose between the Cobalt, which comes with a 6.5" view monitor with NTSC video output to facilitate recording, or the compact and rugged Ranger, which offers an integrated 3.5" screen.

No Comments